$R_{esponse} E_{valuation} In N_{eurofibromatosis} S_{chwannomatosis} \\ INTERNATIONAL COLLABORATION$

- If sharing any data or information from these slides generated by the REiNS International Collaboration, please acknowledge the authors, group chairs, and specific working group.
- If using any information presented with a citation, please reference the primary source.



Assessing established PROs for cNFs: are these scales adequate for clinical trials?

Dominique C. Pichard, MD on behalf of the cNF Working Group September 22, 2019



 $R_{esponse} E_{valuation} I_n N_{eurofibromatosis} S_{chwannomatosis} \\ INTERNATIONAL COLLABORATION$

- cNFs affect more than 99% of adults with NF1
- No malignant potential but have significant negative effects on quality of life
- Current treatment is limited to surgical and destructive methods
- No validated tools to assess improvement on quality of life after treatment of cNFs










Patient-centered cNF research



Lack of data concerning how patients assess morbidity related to cNFs and how they view current and potential cNF treatments



The patient-focused drug development meetings conducted to date have given FDA a deeper appreciation for the expertise that patients and caregivers can bring to the process and the value of incorporating their voice.





A PRO instrument, like physician-based instruments, should be shown to measure the concept it is intended to measure, and the FDA will review the evidence that a particular PRO instrument measures the concept claimed".



FDA Guidance: PRO Measures – Use in medical product development to support labeling claims. 2009⁶

Process



Review the literature for existing PROs that are specific for assessing the skin





- Review of the literature: Skin specific PRO instruments identified
 - Skindex & teen-skindex
 - Dermatology life quality index (DLQI) & CDLQI
 - Adjusted NF QOL (Hilda Crawford)
 - Itch scales
 - Pain scales



Rate PROs

ed Outcomes Rating Acceptance Tool for Endpoints or REINS Committee use only)

Disease-Specific QOL Pain Functional Disability

| Dat | e: |
|---|---------------------|
| pporting its use in neurofibro rmation but needs more work 0=No/poor data/information *Half ratings (.5, 1.5, 2.5) can be used if needed | matosis trials c |
| Rating Criteria | Rating (0-3): |
| 1. <u>Patient characteristics</u> : Age range (e.g., child, adolescent, adult) | use in NF trials |
| Normative groups (e.g., general, NF, oncology, other, # subjects) | |
| 2. <u>Used in published studies</u> : Number and types of studies (e.g., descriptive, clinical trials) | |
| 3. <u>Domains assessed/Item content:</u> Number/description (e.g., physical, social, emotional, cognitive) | |
| 4. <u>Scores available</u> : Item response format (e.g., Likert scale, visual analog scale) | |
| Types of scores (e.g., raw, standardized, domain, total) | |

Neu

tosis & Schwar

| 5. <u>Psychometric Data</u> : Reliability (e.g., internal consistency, test/retest) | |
|--|---------------|
| Validity (e.g., construct, discriminative) | |
| Factor analysis | |
| 6. <u>Feasibility</u> : Cost | |
| Length (number of items) | |
| Ease of administration | |
| Recall period assessed (e.g., 1 week, 24 hours) | |
| Availability in different languages/International use | |
| Overall Impression for use in NF Clinical Trials (Pros'Cons): Rectangu | Total (mean): |
| | |
| | |
| | |

Level of Acceptance (Committee decision):

Primary outcome measure

Secondary outcome measure

Not acceptable at this time/further information needed (specify) Not acceptable (no further review)

Committee notes/comments/additional information needed/plan:

| | HOW OFTEN DURING THE PAST FOUR WEEKS DO THESE STATEMENTS DESCRIBE YOU? | NEVER | RARELY | SOMETIMES | OFTEN | ALL THE TIME |
|-------|---|------------|--------|-----------|-------|-----------------|
| | 1. My skin hurts | | | □₃ | □₄ | □₅ |
| | 2. My skin condition affects how well I sleep | | | □₃ | □₄ | □₅ |
| | 3. I worry that my skin condition may be serious | | | □₃ | | □₅ |
| | 4. My skin condition makes it hard to work or do hobbies | | | < □₃ | □₄ | □₅ |
| | 5. My skin condition affects my social life | | - B | □3 | □₄ | □₅ |
| | 6. My skin condition makes me feel depressed | | | □₃ | □₄ | □₅ |
| | 7. My skin condition burns or stings | ્રેષ્ટ્ર | | □₃ | □₄ | □₅ |
| | 8. I tend to stay at home because of my skin condition | N . | | □₃ | □₄ | □s |
| | 9. I worry about getting scars from my skin condition | | | □₃ | □₄ | □s |
| | 10. My skin itches | | | □₃ | | □₅ |
| | 11. My skin condition affects how close I can be with those I love . | | | □₃ | □₄ | □s |
| | 12. I am ashamed of my skin condition | | | □₃ | □₄ | □s |
| | 13. I worry that my skin condition may get worse | | | □₃ | □₄ | □₅ |
| | 14. I tend to do things by myself because of my skin condition . | | | □₃ | □₄ | □₅ |
| | 15. I am angry about my skin condition | | | □₃ | □₄ | □₅ |
| | 18. Water bothers my skin condition (bathing, washing hands) . | | | □₃ | □₄ | □₅ |
| | 17. My skin condition makes showing affection difficult | | | □₃ | □₄ | □s |
| | 18. I worry about side-effects from skin medications / treatments . | | | □₃ | □₄ | □₅ |
| a a | 19. My skin is irritated | | | □₃ | □₄ | □₅ |
| Porte | 20. My skin condition affects my interactions with others | | | □₃ | □₄ | |

se Evalu

is & Sch

10

| HOW OFTEN DURING THE PAST 4 WEEK DO THESE STATEMENTS DESCRIBE YOU? | NEVER | RARELY | SOMETIMES |
|---|-------|----------|-------------|
| 21. I am embarrassed by my skin condition | | | □₃ |
| 22. My skin condition is a problem for the people I love | | | |
| 23. I am frustrated by my skin condition | | | |
| 24. My skin is sensitive | | | □₃ |
| 25. My skin condition affects my desire to be with people | | <u> </u> | □, |
| 26. I am humiliated by my skin condition | | GE2 | |
| 27. My skin condition bleeds | | | \square_3 |
| 28. I am annoyed by my skin condition | ¢, | | |
| 29. My skin condition interferes with my sex life . | | | |
| 30. My skin condition makes me tired | | | □₃ |



S K

Ν

D E X Skindex PRO RATE Overall impression: 2.54/3.0


PROS

- Ages 12-17, ≥18
- Used widely in general derm.
- Qs appropriate for cNFs
- Feasibility

CONS

- No interventional trial data
- Questions not relevant to NF1
- "my skin condition"







GOVERNMENT




Skindex Scores









| 1. | Over the last week, how itchy , sore , painful or stinging has your skin been? | Very much A lot A little Not at all | | |
|-----|--|--|--------------|--|
| 2. | Over the last week, how embarrassed or self conscious have you been because of your skin? | Very much A lot A little Not at all | | |
| 3. | Over the last week, how much has your skin interfered with you going shopping or looking after your home or garden ? | Very much A lot A little Not at all | Not relevant | |
| 4. | Over the last week, how much has your skin influenced the clothes you wear? | Very much A lot A little Not at all | Not relevant | |
| 5. | Over the last week, how much has your skin affected any social or leisure activities? | Very much A lot A little Not at all | Not relevant | |
| 6. | Over the last week, how much has your skin made it difficult for you to do any sport ? | Very much A lot A little Not at all | Not relevant | |
| 7. | Over the last week, has your skin prevented you from working or studying ? | Yes No | Not relevant | |
| | If "No", over the last week how much has your skin been a problem at work or studying ? | A lot A little Not at all | | |
| 8. | Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives ? | Very much A lot A little Not at all | Not relevant | |
| 9. | Over the last week, how much has your skin caused any sexual difficulties? | Very much A lot A little Not at all | Notrelevant | |
| 10. | Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time? | Very much A lot A little | | |





C D L Q I



(C)DLQI PRO RATE

Overall impression: 2.5/3.0 (2.65/3)

PROS

- Ages 4-16, ≥16
- Used widely in derm. (>1000 pub)
- Qs appropriate for cNFs
- Feasibility

CONS

- No interventional trial data
- Multiple domains in single question
- Raw score, interpretation is not validated





Future directions

- Skindex: modifications to change wording from "my skin" to "my cutaneous neurofibromas"
 - Makes scale more specific to cNFs
 - Helps patients not rate skin AEs of a drug
- DLQI: modifications to the scale is more broad
 - Questions that have multiple domains need to be separated
 - Will require rewriting multiple questions and keeping the questionnaire an appropriate length and understandability



• ? Develop de novo cNF PRO

Acknowledgements

- Pam Wolters
- Dawn Siegel
- Khaled Ezzedine,
- Betty Schorry
- Carolina Barnett Tapia

REiNS PRO and cNF working groups

Ashley Cannon, UAB

